ChiCTR2400086367 版本V1.0 版本创建时间2024/06/29 21:49:24 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400086367 

最近更新日期:

Date of Last Refreshed on:

2024-06-29 21:49:13 

注册时间:

Date of Registration:

2024-06-29 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

对比硬脊膜穿破硬膜外技术(DPE)分娩镇痛下不同浓度罗哌卡因首剂量的ED90:一项随机序列分配研究

Public title:

Determination the ED90s of different concentrations of initial ropivacaine dose for labor analgesia with dural puncture epidural (DPE): A randomized sequential allocation study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

对比硬脊膜穿破硬膜外技术(DPE)分娩镇痛下不同浓度罗哌卡因首剂量的ED90:一项随机序列分配研究

Scientific title:

Determination the ED90s of different concentrations of initial ropivacaine dose for labor analgesia with dural puncture epidural (DPE): A randomized sequential allocation study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

熊祥生 

研究负责人:

熊祥生 

Applicant:

Xiangsheng Xiong 

Study leader:

Xiangsheng Xiong 

申请注册联系人电话:

Applicant telephone:

+86 177 9898 2001

研究负责人电话:

Study leader's telephone:

+86 177 9898 2001

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

158193942@qq.com

研究负责人电子邮件:

Study leader's E-mail:

158193942@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省淮安市淮阴区淮河东路1号

研究负责人通讯地址:

江苏省淮安市淮阴区淮河东路1号

Applicant address:

The Fifth People's Hospital of Huaian, 1 Huaihe East Road, Huaian, Jiangsu

Study leader's address:

The Fifth People's Hospital of Huaian, 1 Huaihe East Road, Huaian, Jiangsu

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

扬州大学附属淮安医院(淮安市第五人民医院)

Applicant's institution:

Huai'an Hospital Affiliated to Yangzhou University (The Fifth People's Hospital of Huai'an)

研究负责人所在单位:

扬州大学附属淮安医院(淮安市第五人民医院)

Affiliation of the Leader:

Huai'an Hospital Affiliated to Yangzhou University (The Fifth People's Hospital of Huai'an)

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY-P-2024-009-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

扬州大学附属淮安医院(淮安市第五人民医院)伦理委员会

Name of the ethic committee:

Ethics Committee of the Huai'an Hospital Affiliated to Yangzhou University (The Fifth People's Hospital of Huai'an)

伦理委员会批准日期:

Date of approved by ethic committee:

2024-05-31 00:00:00

伦理委员会联系人:

郭云虎

Contact Name of the ethic committee:

Yunhu Guo

伦理委员会联系地址:

江苏省淮安市淮阴区淮河东路1号

Contact Address of the ethic committee:

Huai'an Hospital Affiliated to Yangzhou University (The Fifth People's Hospital of Huai'an), 1 Huaihe East Road, Huaian, Jiangsu

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 517 8967 0057

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

扬州大学附属淮安医院(淮安市第五人民医院)

Primary sponsor:

Huai'an Hospital Affiliated to Yangzhou University (The Fifth People's Hospital of Huai'an)

研究实施负责(组长)单位地址:

江苏省淮安市淮阴区淮河东路1号

Primary sponsor's address:

Huai'an Hospital Affiliated to Yangzhou University (The Fifth People's Hospital of Huai'an), 1 Huaihe East Road, Huaian, Jiangsu

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

Country:

China

Province:

Jiangsu

City:

单位(医院):

扬州大学附属淮安医院(淮安市第五人民医院)

具体地址:

江苏省淮安市淮阴区淮河东路1号

Institution
hospital:

Huai'an Hospital Affiliated to Yangzhou University (The Fifth People's Hospital of Huai'an)

Address:

Huai'an Hospital Affiliated to Yangzhou University (The Fifth People's Hospital of Huai'an), 1 Huaihe East Road, Huaian, Jiangsu

经费或物资来源:

淮安市科技计划项目;自筹

Source(s) of funding:

Science and technology plan project of Huaian; Self-financing

Target disease:

N/A

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探索硬脊膜穿破硬膜外技术(DPE)分娩镇痛下不同浓度罗哌卡因首剂量的ED90。  

Objectives of Study:

Determination the ED90s of different concentrations of initial ropivacaine dose for labor analgesia with dural puncture epidural (DPE)

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①年龄18-40岁单胎足月妊娠(包括初产和经产妇)拟椎管内镇痛下行分娩镇痛者;②宫颈扩张<5cm;VAS评分>5分;③ASA分级I-II级

Inclusion criteria

Women aged 18-40 with a single term pregnancy who request epidural labor analgesia should have a cervical dilation of < 5 cm, a visual analogue scale (VAS) score > 5, and an American Society of Anesthesiologists physical status I-II.

排除标准:

①椎管内镇痛禁忌者;②高血压者(包括慢性高血压;妊娠期高血压及子痫前期);③妊娠期糖尿病;④巨大儿;⑤体重指数;⑥BMI≥40kg/m2;⑦胎儿窘迫;⑧采用其它方式镇痛者;⑨罗哌卡因或舒芬太尼禁忌者

Exclusion criteria:

Intraspinal analgesia is contraindicated; Hypertension (including chronic hypertension, hypertension, and preeclampsia during pregnancy), gestational diabetes mellitus, giant fetus, BMI >=40kg/m^2, fetal distress, or patients who use other methods of analgesia are all contraindications for this procedure. Additionally, the use of ropivacaine or sufentanil is also contraindicated.

研究实施时间:

Study execute time:

From 2024-07-01 00:00:00 To 2025-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-07-01 00:00:00 To 2025-06-30 00:00:00  

干预措施:

Interventions:

组别:

0.075%组

样本量:

30

Group:

0.075% Group

Sample size:

干预措施:

0.075%罗哌卡因10ml+舒芬太尼0.3ug/ml

干预措施代码:

Intervention:

10 mL of 0.075% ropivacaine with 0.3 μg/mL of sufentanil

Intervention code:

组别:

0.1%组

样本量:

30

Group:

0.1% Group

Sample size:

干预措施:

0.1%罗哌卡因10ml+舒芬太尼0.3ug/ml

干预措施代码:

Intervention:

10 mL of 0.1% ropivacaine with 0.3 μg/mL of sufentanil

Intervention code:

组别:

0.125%组

样本量:

30

Group:

0.125% Group

Sample size:

干预措施:

0.125%罗哌卡因10ml+舒芬太尼0.3ug/ml

干预措施代码:

Intervention:

10 mL of 0.125% ropivacaine with 0.3 μg/mL of sufentanil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China 

Province:

Jiangsu 

City:

 

单位(医院):

扬州大学附属淮安医院(淮安市第五人民医院) 

单位级别:

三级 

Institution
hospital:

Huai'an Hospital Affiliated to Yangzhou University (The Fifth People's Hospital of Huai'an)

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

满足产妇在首次予以罗哌卡因镇痛需求(30分钟时VAS评分<3分)的ED90

指标类型:

主要指标

Outcome:

The ED90 of initial ropivacaine dose with dural puncture epidural (DPE)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

VAS评分

指标类型:

次要指标

Outcome:

visual analogue scale (VAS) score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Bromage评分

指标类型:

次要指标

Outcome:

Bromage score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Apgar评分

指标类型:

次要指标

Outcome:

Apgar score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良事件

指标类型:

次要指标

Outcome:

adverse event

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 40 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

计算机生成的随机序列被放入密封的不透明信封中,并按顺序编号

Randomization Procedure (please state who generates the random number sequence and by what method):

A computer-generated randomisation sequence was placed into sealed opaque envelopes and sequentially numbered.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

双盲

Blinding:

Double blinded

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

自制指标记录表格

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Self-made record table for indicators

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-06-29 21:49:13